[go: up one dir, main page]

KR960700732A - 타로신 함유 방출 억제 수의학적 조성물(tylosin containing sustained release veterinary compositions) - Google Patents

타로신 함유 방출 억제 수의학적 조성물(tylosin containing sustained release veterinary compositions) Download PDF

Info

Publication number
KR960700732A
KR960700732A KR1019950704128A KR19950704128A KR960700732A KR 960700732 A KR960700732 A KR 960700732A KR 1019950704128 A KR1019950704128 A KR 1019950704128A KR 19950704128 A KR19950704128 A KR 19950704128A KR 960700732 A KR960700732 A KR 960700732A
Authority
KR
South Korea
Prior art keywords
composition
release inhibiting
inhibiting composition
weight
tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019950704128A
Other languages
English (en)
Other versions
KR100283369B1 (ko
Inventor
패터슨 알랜
홀메스 드루
Original Assignee
패터슨 알랜
노르브룩 라보라토리즈 리미팃드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 패터슨 알랜, 노르브룩 라보라토리즈 리미팃드 filed Critical 패터슨 알랜
Publication of KR960700732A publication Critical patent/KR960700732A/ko
Application granted granted Critical
Publication of KR100283369B1 publication Critical patent/KR100283369B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

근육 내 및 피하 투여를 위한 방출 억제 조성물은 티로신 및 겔화제를 함유한 유성 부형제로 구성되고, 이때 겔화제는 스테아르산과 같은 지방산의 알루미늄 염일 수 있고 유성 부형제는 프로필렌 글리콜 다카프릴레이트/디카프레이트와 같은 단사슬 천연 유도 지방산의 낮은 점도 폴리올 디에스테르일 수 있다.

Description

타로신 함유 방출 억제 수의학적 조성물(TYLOSIN CONTAINING SUSTAINED RELEASE VETERINARY COMPOSITIONS)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (20)

  1. 티로신 및 겔화제를 함유한 유성 부형제로 구성되는 방출 억제 조성물.
  2. 제1항에 있어서, 겔화제가 지방산의 알루미늄 염인 방출 억제 조성물.
  3. 제2항에 있어서, 지방산이 스테아르산인 방출 억제 조성물.
  4. 제1항 또는 2항에 있어서, 유성 부형제가 단사슬 천연 유도 지방산의 낮은 점도 폴리올 디에스테르인 방출 억제 조성물.
  5. 제4항에 있어서, 유성 부형제가 프로필렌 글리콜인 방출 억제 조성물.
  6. 제1항에 있어서, 유성 부형제가 상품명 "Neobee Oil"으로 입수가능한 부형제인 방출 억제 조성물.
  7. 제1항 또는 2항에 있어서, 유성 부형제가 조성물의 70-90중량% 양으로 존재하는 방출 억제 조성물.
  8. 제1항 또는 2항에 있어서, 유성 부형제가 조성물의 74중량% 양으로 존재하는 방출 억제 조성물.
  9. 제3항에 있어서, 겔화제가 알루미늄 디스테아레이트인 방출 억제 조성물.
  10. 제9항에 있어서, 알루미늄 디스테아레이트가 조성물의 0.75-1.25중량% 양으로 존재하는 방출 억제 조성물.
  11. 제9항에 있어서, 알루미늄 디스테아레이트가 조성물의 0.94중량% 양으로 존재하는 방출 억제 조성물.
  12. 제3항에 있어서, 겔화제가 알루미늄 모노스테아레이트, 알루미늄 디스테아레이트 및 알루미늄 트리스테아레이트로 구성되는 군으로부터 선택되는 방출 억제 조성물.
  13. 제12항에 있어서, 알루미늄 모노스테아레이트가 1-3중량% 양으로 존재하는 방출 억제 조성물.
  14. 제12항에 있어서, 알루미늄 모노스테아레이트가 1.8중량% 양으로 조재하는 방출 억제 조성물.
  15. 마크로라이드 항생물질, 예를 들면, 티로신과 같은 활성 성분을 유성 부형제 내로 병합하는 방법으로서, 입자의 90%가 Coulter Counter 기술을 사용하여 측정한 바와 같이 25㎛ 미만의 주요 크기를 갖도록 상기 활성 성분의 입자 크기를 조절하고 상기 활성 성분을 상기 유성 부형제 내로 혼합하는 것으로 구성되는 방법.
  16. 제15항에 있어서, 활성 성분이 티로신이고 상기는 단위 부피 당 3-30중량%의 양으로 존재하는 방법.
  17. 제15항에 있어서, 입자의 90%가 10㎛ 미만의 주요 크기를 갖도록 활성 성분의 입자 범위를 조절하는 방법.
  18. 근육 내 및 피하 투여를 위한 수의학적 제제를 제조하는 방법으로서, 하기 단계로 구성되는 방법: (ⅰ) 제약학적으로 허용가능한 부형제 및 방출 억제 특성을 부여하는 약제를 혼합하고 충분한 열을 가하여 충분히 혼합시키고, (ⅱ) 혼합물을 냉각시켜 겔 기부를 형성하고, 및 (ⅲ) 티로신을 첨가하여 겔 기부내 상기의 현탁액을 형성한다.
  19. 제18항에 있어서, 티로신의 농도가 150㎎/㎖인 방법.
  20. 티로신에 민감함 세균에 의한 감염에 대항하기 위해 가축을 처리하는 방법으로서, 티로신 및 결화제를 함유한 유성 부형제로 구성되는 방출 억제 조성물을 단일 경우에 투여되는 20-30㎎/㎖/㎏(체중)의 양으로 상기에 근육 내 및 피하 투여하는 것으로 구성되는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950704128A 1993-03-24 1994-03-22 타로신 함유 방출 억제 수의학적 조성물 Expired - Lifetime KR100283369B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9306106.7 1993-03-24
GB939306106A GB9306106D0 (en) 1993-03-24 1993-03-24 Sustained release veterinary composition
PCT/GB1994/000578 WO1994021267A1 (en) 1993-03-24 1994-03-22 Tylosin containing sustained release veterinary compositions

Publications (2)

Publication Number Publication Date
KR960700732A true KR960700732A (ko) 1996-02-24
KR100283369B1 KR100283369B1 (ko) 2001-03-02

Family

ID=10732660

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950704128A Expired - Lifetime KR100283369B1 (ko) 1993-03-24 1994-03-22 타로신 함유 방출 억제 수의학적 조성물

Country Status (23)

Country Link
EP (1) EP0689444B1 (ko)
JP (1) JPH08508032A (ko)
KR (1) KR100283369B1 (ko)
CN (1) CN1096268C (ko)
AT (1) ATE181834T1 (ko)
AU (1) AU669435B2 (ko)
BG (1) BG62352B1 (ko)
BR (1) BR9406202A (ko)
CA (1) CA2158662C (ko)
DE (1) DE69419408T2 (ko)
DK (1) DK0689444T3 (ko)
ES (1) ES2135568T3 (ko)
FI (1) FI954447L (ko)
GB (1) GB9306106D0 (ko)
GR (1) GR3031293T3 (ko)
HU (1) HUT73424A (ko)
IL (1) IL109053A (ko)
NO (1) NO953647L (ko)
NZ (1) NZ262756A (ko)
PE (1) PE7595A1 (ko)
PL (1) PL175127B1 (ko)
RO (1) RO114738B1 (ko)
WO (1) WO1994021267A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2130069B1 (es) * 1997-04-10 2000-03-01 Basf Labiana S A Preparacion farmaceutica con liberacion retardada del producto activo.
US6946137B2 (en) * 2001-10-19 2005-09-20 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
CN1326526C (zh) * 2002-10-25 2007-07-18 英特威国际有限公司 延长释放的药物组合物
MD4037666T2 (ro) 2020-12-08 2024-09-30 Ruminant Biotech Corp Ltd Îmbunătățiri ale dispozitivelor și metodelor de furnizare a substanțelor la animale
CN116407505A (zh) * 2023-03-28 2023-07-11 青岛康地恩动物药业有限公司 一种高生物利用度泰万菌素干混悬剂及制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2105589B (en) * 1981-09-11 1985-10-23 Wellcome Found Injectable suspensions containing maleic acid or a salt thereof as a stabilising agent
PT76448B (en) * 1982-04-05 1986-03-20 Merck Sharp & Dohme Process for preparing stabilization of unstable drugs or food supplements containing antibiotics mainly ephrotomycin
US4597969A (en) * 1982-04-05 1986-07-01 Merck Sharp & Dohme Stabilization of unstable drugs or food supplements
ES2024444B3 (es) * 1986-03-10 1992-03-01 American Cyanamid Co Metodo para la preparacion de formulacion de pildoras gruesas de liberacion sostenida.
US4994227A (en) * 1986-03-10 1991-02-19 American Cyanamid Company Method for the preparation of sustained released bolus formulation

Also Published As

Publication number Publication date
CA2158662A1 (en) 1994-09-29
AU669435B2 (en) 1996-06-06
NO953647D0 (no) 1995-09-15
BR9406202A (pt) 1995-12-12
GR3031293T3 (en) 1999-12-31
CN1123525A (zh) 1996-05-29
KR100283369B1 (ko) 2001-03-02
PE7595A1 (es) 1995-04-25
PL310804A1 (en) 1996-01-08
HU9502700D0 (en) 1995-11-28
GB9306106D0 (en) 1993-05-12
IL109053A (en) 1999-09-22
JPH08508032A (ja) 1996-08-27
ATE181834T1 (de) 1999-07-15
NO953647L (no) 1995-11-22
RO114738B1 (ro) 1999-07-30
HUT73424A (en) 1996-07-29
DE69419408D1 (de) 1999-08-12
FI954447A0 (fi) 1995-09-20
PL175127B1 (pl) 1998-11-30
ES2135568T3 (es) 1999-11-01
FI954447L (fi) 1995-11-15
DK0689444T3 (da) 1999-11-22
EP0689444A1 (en) 1996-01-03
CN1096268C (zh) 2002-12-18
WO1994021267A1 (en) 1994-09-29
BG62352B1 (bg) 1999-09-30
IL109053A0 (en) 1994-06-24
DE69419408T2 (de) 1999-10-28
NZ262756A (en) 1997-06-24
AU6262194A (en) 1994-10-11
CA2158662C (en) 2009-06-30
BG100078A (bg) 1996-07-31
EP0689444B1 (en) 1999-07-07

Similar Documents

Publication Publication Date Title
EP1028723B1 (en) Stabilized ascorbic acid, composition, and method of use
JP2565513B2 (ja) メラニン生成抑制外用薬剤
US4963555A (en) Formulations of heterocyclic compounds
NL8201413A (nl) Farmaceutische preparaten voor plaatselijke toepassing en werkwijzen voor het bereiden en toepassen van deze preparaten.
CA1172169A (en) Formulations of heterocyclic compounds
US20070292462A1 (en) Surfactant, and an emulsion-type cosmetic composition and a liposome containing said surfactant
JP2929304B2 (ja) 美白用皮膚外用剤
KR960700062A (ko) 산성 pH에서의 안정성을 개선시키기 위해 변형된 올리고누클레오티드(OLIGONUCLEOTIDES MODIFIED TO IMPROVE STABILITY AT ACIC pH)
CA2074348C (en) Stable compositions for parenteral administration and their use
JP2000513364A (ja) ビタミンｃ送達システム
KR940703658A (ko) 허혈 및 재관류로 인한 조직 손상을 개선하기 위한 방법 및 조성물(method and composition for ameliorating tissue damage due to ischemia and reperfution)
EP1194169B1 (en) Stabilized vitamin c formulations
WO2000001390A1 (en) Topical aciclovir formulations
WO1994005258A1 (en) An antivirally active pharmaceutical oil-in-water emulsion containing 9-[(2-hydroxyethoxy)methyl]guanine (acyclovir) or a salt or ester thereof
KR960700732A (ko) 타로신 함유 방출 억제 수의학적 조성물(tylosin containing sustained release veterinary compositions)
JP2549127B2 (ja) メラニン生成抑制外用薬剤
AU624222B2 (en) Compositions containing thymopentin for topical treatment of skin disorders
KR880000432A (ko) 4(3H)-옥소-5,6,7,8-테트라히드로피리도-2,3-d 피리미딘 유도체
KR20000068285A (ko) 경피흡수성이 양호하며 또한 피부자극성이 적은 염산아젤라스틴함유 경피제제
EP0105448A1 (en) The use of undecylenic acid for the manufacture of a composition for the treatment of Herpes labialis
CA2022632A1 (en) Pharmaceutical formulation
TH18460A (th) สารผสมทางสัตวแพทย์ ที่ปลดปล่อยแบบถูกหน่วงเหนี่ยวที่มีไทลอซิน
TH13141B (th) สารผสมทางสัตวแพทย์ ที่ปลดปล่อยแบบถูกหน่วงเหนี่ยวที่มีไทลอซิน
CA1207238A (en) Use of haloprogin in the treatment of herpes labialis
JP3285619B2 (ja) 皮膚外用剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19950923

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19990320

Comment text: Request for Examination of Application

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20001024

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20001207

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20001208

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20031119

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20041124

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20051121

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20061127

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20071116

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20081111

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20091123

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20101124

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20111122

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20111122

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20121123

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20121123

Start annual number: 13

End annual number: 13

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20140922

Termination category: Expiration of duration